Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy.

Journal Article

BACKGROUND: Previous studies suggest that efficacy is more important than side-effect risks to psoriasis patients. However, those studies did not consider potentially fatal risks of biologic treatments. OBJECTIVE: To quantify the risks patients are willing to accept for improvements in psoriasis symptoms. METHODS: Adults with a self-reported physician diagnosis of psoriasis were recruited through the National Psoriasis Foundation. Using a discrete-choice experiment, patients completed a series of nine choice questions, each including a pair of hypothetical treatments. Treatments were defined by severity of plaques, body surface area (BSA), and 10-year risks of tuberculosis, serious infection and lymphoma. RESULTS: For complete clearance of 25% BSA with mild plaques, respondents (n = 1608) were willing to accept a 20% (95% confidence interval: 9-26%) risk of serious infection, 10% (5-15%) risk of tuberculosis and 2% (1-3%) risk of lymphoma. For complete clearance of 25% BSA with severe plaques, respondents were willing to accept a 54% (48-62%) risk of serious infection, 36% (28-49%) risk of tuberculosis and 8% (7-9%) risk of lymphoma. LIMITATIONS: Respondents were asked to evaluate hypothetical scenarios. Actual treatment choices may differ. CONCLUSION: Respondents were willing to accept risks above likely clinical exposures for improvements in psoriasis symptoms. Individual risk tolerances may vary.

Full Text

Duke Authors

Cited Authors

  • Kauf, TL; Yang, J-C; Kimball, AB; Sundaram, M; Bao, Y; Okun, M; Mulani, P; Hauber, AB; Johnson, FR

Published Date

  • 2015

Published In

Volume / Issue

  • 26 / 6

Start / End Page

  • 507 - 513

PubMed ID

  • 25946139

Pubmed Central ID

  • 25946139

Electronic International Standard Serial Number (EISSN)

  • 1471-1753

Digital Object Identifier (DOI)

  • 10.3109/09546634.2015.1034071


  • eng

Conference Location

  • England